These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25382190)

  • 21. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
    Accornero P; Pavone LM; Baratta M
    Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
    Kim KH; Kim H
    Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the discovery of small molecule c-Met Kinase inhibitors.
    Parikh PK; Ghate MD
    Eur J Med Chem; 2018 Jan; 143():1103-1138. PubMed ID: 29157685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.
    Mohyeldin MM; Akl MR; Ebrahim HY; Dragoi AM; Dykes S; Cardelli JA; El Sayed KA
    Oncotarget; 2016 May; 7(22):32247-73. PubMed ID: 27086914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer.
    Boromand N; Hasanzadeh M; ShahidSales S; Farazestanian M; Gharib M; Fiuji H; Behboodi N; Ghobadi N; Hassanian SM; Ferns GA; Avan A
    J Cell Physiol; 2018 Jun; 233(6):4490-4496. PubMed ID: 29058790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Met targeting in advanced gastric cancer: An open challenge.
    Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
    Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in MET tyrosine kinase inhibitors in gastric cancer.
    Zhang Y; Shen L; Peng Z
    Cancer Biol Med; 2024 May; 21(6):484-98. PubMed ID: 38727001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Tolerability of c-MET Inhibitors in Cancer.
    Puccini A; Marín-Ramos NI; Bergamo F; Schirripa M; Lonardi S; Lenz HJ; Loupakis F; Battaglin F
    Drug Saf; 2019 Feb; 42(2):211-233. PubMed ID: 30649748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Showering c-MET-dependent cancers with drugs.
    Knudsen BS; Vande Woude G
    Curr Opin Genet Dev; 2008 Feb; 18(1):87-96. PubMed ID: 18406132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker development in MET-targeted therapy.
    Zhang Y; Du Z; Zhang M
    Oncotarget; 2016 Jun; 7(24):37370-37389. PubMed ID: 27013592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The current state of molecularly targeted drugs targeting HGF/Met.
    Yano S; Nakagawa T
    Jpn J Clin Oncol; 2014 Jan; 44(1):9-12. PubMed ID: 24371262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].
    Song S; Bi M
    Zhongguo Fei Ai Za Zhi; 2014 Oct; 17(10):755-9. PubMed ID: 25342043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.
    van der Horst EH; Chinn L; Wang M; Velilla T; Tran H; Madrona Y; Lam A; Ji M; Hoey TC; Sato AK
    Neoplasia; 2009 Apr; 11(4):355-64. PubMed ID: 19308290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in cancer therapy targeting c-Met signaling pathway.
    Jung KH; Park BH; Hong SS
    Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the HGF/Met signaling pathway in cancer therapy.
    Cecchi F; Rabe DC; Bottaro DP
    Expert Opin Ther Targets; 2012 Jun; 16(6):553-72. PubMed ID: 22530990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.